JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 34 No. 4 689-694
© 1993 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sgouros, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sgouros, G.

Bone Marrow Dosimetry for Radioimmunotherapy: Theoretical Considerations

George Sgouros

Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York

Correspondence: For correspondence and reprints contact: George Sgouros, PhD, Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.

ABSTRACT

In most implementations of radioimmunotherapy, the red marrow is the dose-limiting organ. Estimates of the radioactivity concentration in this organ are usually based on blood sampling or bone marrow biopsy. This work presents a simple equation which may be used to calculate the red marrow-to-blood activity concentration ratio given the hematocrit and the red marrow extracellular fluid fraction of a patient. Also presented are a series of equations which may be used to correct the activity concentration in bone marrow biopsies for bone, yellow marrow and blood contamination. Assuming a hematocrit of 0.47 and a red marrow extracellular fluid fraction of 0.19, the predicted red marrow-to-blood activity concentration ratio is 0.36. This value is consistent with experimental studies. Depending upon the characteristics of the bone marrow biopsy sample, the red marrow activity concentration may be underestimated by a factor of 1.5–5. The correction factor for an "average" biopsy is 2.73. If the cortical bone cap is removed before the sample is weighed and counted, the correction factor is 1.92.




This article has been cited by other articles:


Home page
 JNMHome page
N. Pandit-Taskar, J. A. O'Donoghue, M. J. Morris, E. A. Wills, L. H. Schwartz, M. Gonen, H. I. Scher, S. M. Larson, and C. R. Divgi
Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy
J. Nucl. Med., July 1, 2008; 49(7): 1066 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. F. Meredith, S. Shen, A. Forero, and A. LoBuglio
A Method to Correct for Radioactivity in Large Vessels That Overlap the Spine in Imaging-Based Marrow Dosimetry of Lumbar Vertebrae
J. Nucl. Med., February 1, 2008; 49(2): 279 - 284.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Cremonesi, M. Ferrari, C. M. Grana, A. Vanazzi, M. Stabin, M. Bartolomei, S. Papi, G. Prisco, G. Martinelli, G. Paganelli, et al.
High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment
J. Nucl. Med., November 1, 2007; 48(11): 1871 - 1879.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Paganelli, M. Ferrari, L. Ravasi, M. Cremonesi, C. De Cicco, V. Galimberti, G. Sivolapenko, A. Luini, R. De Santis, L. L. Travaini, et al.
Intraoperative Avidination for Radionuclide Therapy: A Prospective New Development to Accelerate Radiotherapy in Breast Cancer
Clin. Cancer Res., September 15, 2007; 13(18): 5646s - 5651s.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. Sgouros
Toward Patient-Friendly Cell-Level Dosimetry
J. Nucl. Med., April 1, 2007; 48(4): 496 - 497.
[Full Text] [PDF]

Home page
 JNMHome page
L. Martensson, R. Nilsson, T. Ohlsson, H.-O. Sjogren, S.-E. Strand, and J. Tennvall
Reduced Myelotoxicity with Sustained Tumor Concentration of Radioimmunoconjugates in Rats after Extracorporeal Depletion
J. Nucl. Med., February 1, 2007; 48(2): 269 - 276.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Persson, L. Gedda, H. Lundqvist, V. Tolmachev, H. Nordgren, P.-U. Malmstrom, and J. Carlsson
[177Lu]Pertuzumab: Experimental Therapy of HER-2-Expressing Xenografts
Cancer Res., January 1, 2007; 67(1): 326 - 331.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. M. Brindle, A. A. Trindade, A. P. Shah, D. W. Jokisch, P. W. Patton, J. C. Pichardo, and W. E. Bolch
Linear Regression Model for Predicting Patient-Specific Total Skeletal Spongiosa Volume for Use in Molecular Radiotherapy Dosimetry
J. Nucl. Med., November 1, 2006; 47(11): 1875 - 1883.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Cremonesi, M. Ferrari, L. Bodei, G. Tosi, and G. Paganelli
Dosimetry in Peptide Radionuclide Receptor Therapy: A Review
J. Nucl. Med., September 1, 2006; 47(9): 1467 - 1475.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. N. Mamelak, S. Rosenfeld, R. Bucholz, A. Raubitschek, L. B. Nabors, J. B. Fiveash, S. Shen, M.B. Khazaeli, D. Colcher, A. Liu, et al.
Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults With Recurrent High-Grade Glioma
J. Clin. Oncol., August 1, 2006; 24(22): 3644 - 3650.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Pagel, F. R. Appelbaum, J. F. Eary, J. Rajendran, D. R. Fisher, T. Gooley, K. Ruffner, E. Nemecek, E. Sickle, L. Durack, et al.
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
Blood, March 1, 2006; 107(5): 2184 - 2191.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Berndorff, S. Borkowski, S. Sieger, A. Rother, M. Friebe, F. Viti, C. S. Hilger, J. E. Cyr, and L. M. Dinkelborg
Radioimmunotherapy of Solid Tumors by Targeting Extra Domain B Fibronectin: Identification of the Best-Suited Radioimmunoconjugate
Clin. Cancer Res., October 1, 2005; 11(19): 7053s - 7063s.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. A. Siegel, R. B. Sparks, R. M. Sharkey, B. W. Wessels, W. E. Bolch, L. G. Bouchet, H. B. Breitz, R. F. Meredith, G. Sgouros, and M. G. Stabin
Blood-Based Red Marrow Dosimetry: Where's the Beef?
J. Nucl. Med., August 1, 2005; 46(8): 1404 - 1406.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Linden, C. Hindorf, E. Cavallin-Stahl, W. A. Wegener, D. M. Goldenberg, H. Horne, T. Ohlsson, L. Stenberg, S.-E. Strand, and J. Tennvall
Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab
Clin. Cancer Res., July 15, 2005; 11(14): 5215 - 5222.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Shen, S. J. DeNardo, C. M. Richman, A. Yuan, C. H. Siantar, R. T. O'Donnell, L. A. Kroger, and G. L. DeNardo
Planning Time for Peripheral Blood Stem Cell Infusion After High-Dose Targeted Radionuclide Therapy Using Dosimetry
J. Nucl. Med., June 1, 2005; 46(6): 1034 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Vallabhajosula, S. J. Goldsmith, K. A. Hamacher, L. Kostakoglu, S. Konishi, M. I. Milowski, D. M. Nanus, and N. H. Bander
Prediction of Myelotoxicity Based on Bone Marrow Radiation-Absorbed Dose: Radioimmunotherapy Studies Using 90Y- and 177Lu-Labeled J591 Antibodies Specific for Prostate-Specific Membrane Antigen
J. Nucl. Med., May 1, 2005; 46(5): 850 - 858.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Lassmann, H. Hanscheid, C. Reiners, S. R. Thomas, B. de Keizer, J. M.H. de Klerk, and M. W. Konijnenberg
Blood and Bone Marrow Dosimetry in Radioiodine Therapy of Differentiated Thyroid Cancer After Stimulation with rhTSH
J. Nucl. Med., May 1, 2005; 46(5): 900 - 901.
[Full Text] [PDF]

Home page
 JNMHome page
G. Sgouros
Blood and Bone Marrow Dosimetry in Radioiodine Therapy of Thyroid Cancer
J. Nucl. Med., May 1, 2005; 46(5): 899 - 900.
[Full Text] [PDF]

Home page
 JNMHome page
R. M. Sharkey, G. Hajjar, D. Yeldell, A. Brenner, J. Burton, A. Rubin, and D. M. Goldenberg
A Phase I Trial Combining High-Dose 90Y-Labeled Humanized Anti-CEA Monoclonal Antibody with Doxorubicin and Peripheral Blood Stem Cell Rescue in Advanced Medullary Thyroid Cancer
J. Nucl. Med., April 1, 2005; 46(4): 620 - 633.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
B. Lambert, K. Bacher, L. Defreyne, F. Gemmel, H. Van Vlierberghe, J. M. Jeong, R. A. Dierckx, C. Van de Wiele, H. Thierens, and F. De Vos
188Re-HDD/Lipiodol Therapy for Hepatocellular Carcinoma: A Phase I Clinical Trial
J. Nucl. Med., January 1, 2005; 46(1): 60 - 66.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. Sgouros
Dosimetry of Internal Emitters
J. Nucl. Med., January 1, 2005; 46(1_suppl): 18S - 27S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
P. B. Zanzonico, R. Finn, K. S. Pentlow, Y. Erdi, B. Beattie, T. Akhurst, O. Squire, M. Morris, H. Scher, T. McCarthy, et al.
PET-Based Radiation Dosimetry in Man of 18F-Fluorodihydrotestosterone, a New Radiotracer for Imaging Prostate Cancer
J. Nucl. Med., November 1, 2004; 45(11): 1966 - 1971.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
B. W. Wessels, W. E. Bolch, L. G. Bouchet, H. B. Breitz, G. L. DeNardo, R. F. Meredith, M. G. Stabin, and G. Sgouros
Bone Marrow Dosimetry Using Blood-Based Models for Radiolabeled Antibody Therapy: A Multiinstitutional Comparison
J. Nucl. Med., October 1, 2004; 45(10): 1725 - 1733.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
B. de Keizer, A. Hoekstra, M. W. Konijnenberg, F. de Vos, B. Lambert, P. P. van Rijk, C. J.M. Lips, and J. M.H. de Klerk
Bone Marrow Dosimetry and Safety of High 131I Activities Given After Recombinant Human Thyroid-Stimulating Hormone to Treat Metastatic Differentiated Thyroid Cancer
J. Nucl. Med., September 1, 2004; 45(9): 1549 - 1554.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. R. Divgi, J. A. O'Donoghue, S. Welt, J. O'Neel, R. Finn, R. J. Motzer, A. Jungbluth, E. Hoffman, G. Ritter, S. M. Larson, et al.
Phase I Clinical Trial with Fractionated Radioimmunotherapy Using 131I-Labeled Chimeric G250 in Metastatic Renal Cancer
J. Nucl. Med., August 1, 2004; 45(8): 1412 - 1421.
[Abstract] [Full Text] [PDF]

Home page
 Radiat Prot DosimetryHome page
A. C. Traino, F. Di Martino, G. Boni, G. Mariani, and M. Lazzeri
A minimally invasive method to evaluate 131I kinetics in blood
Radiat Prot Dosimetry, July 1, 2004; 109(3): 249 - 252.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
K. Liepe, R. Hliscs, J. Kropp, R. Runge, F. F. Knapp Jr., and W.-G. Franke
Dosimetry of 188Re-Hydroxyethylidene Diphosphonate in Human Prostate Cancer Skeletal Metastases
J. Nucl. Med., June 1, 2003; 44(6): 953 - 960.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. P. Shah, P. W. Patton, D. A. Rajon, and W. E. Bolch
Adipocyte Spatial Distributions in Bone Marrow: Implications for Skeletal Dosimetry Models
J. Nucl. Med., May 1, 2003; 44(5): 774 - 783.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
G. A. Wiseman, E. Kornmehl, B. Leigh, W. D. Erwin, D. A. Podoloff, S. Spies, R. B. Sparks, M. G. Stabin, T. Witzig, and C. A. White
Radiation Dosimetry Results and Safety Correlations from 90Y-Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma: Combined Data from 4 Clinical Trials
J. Nucl. Med., March 1, 2003; 44(3): 465 - 474.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. A. Siegel, M. G. Stabin, R. B. Sparks, J. Huberty, K. K. Matthay, R. Hawkins, and B. Hasegawa
Total-Body and Red Marrow Dose Estimates
J. Nucl. Med., February 1, 2003; 44(2): 320 - 323.
[Full Text]

Home page
 JNMHome page
J. A. Siegel, D. Yeldell, D. M. Goldenberg, M. G. Stabin, R. B. Sparks, R. M. Sharkey, A. Brenner, and R. D. Blumenthal
Red Marrow Radiation Dose Adjustment Using Plasma FLT3-L Cytokine Levels: Improved Correlations Between Hematologic Toxicity and Bone Marrow Dose for Radioimmunotherapy Patients
J. Nucl. Med., January 1, 2003; 44(1): 67 - 76.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. E. Juweid
Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice
J. Nucl. Med., November 1, 2002; 43(11): 1507 - 1529.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Shen, R. F. Meredith, J. Duan, D. J. Macey, M.B. Khazaeli, F. Robert, and A. F. LoBuglio
Improved Prediction of Myelotoxicity Using a Patient-Specific Imaging Dose Estimate for Non-Marrow-Targeting 90Y-Antibody Therapy
J. Nucl. Med., September 1, 2002; 43(9): 1245 - 1253.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Reardon, G. Akabani, R. Edward Coleman, A. H. Friedman, H. S. Friedman, J. E. Herndon II, I. Cokgor, R. E. McLendon, C. N. Pegram, J. M. Provenzale, et al.
Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas
J. Clin. Oncol., March 1, 2002; 20(5): 1389 - 1397.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. E. Bolch, P. W. Patton, D. A. Rajon, A. P. Shah, D. W. Jokisch, and B. A. Inglis
Considerations of Marrow Cellularity in 3-Dimensional Dosimetric Models of the Trabecular Skeleton
J. Nucl. Med., January 1, 2002; 43(1): 97 - 108.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Bunjes, I. Buchmann, C. Duncker, U. Seitz, J. Kotzerke, M. Wiesneth, D. Dohr, M. Stefanic, A. Buck, S. V. Harsdorf, et al.
Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study
Blood, August 1, 2001; 98(3): 565 - 572.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. Stein, S. V. Govindan, S. Chen, L. Reed, H. Richel, G. L. Griffiths, H. J. Hansen, and D. M. Goldenberg
Radioimmunotherapy of a Human Lung Cancer Xenograft with Monoclonal Antibody RS7: Evaluation of 177Lu and Comparison of Its Efficacy with That of 90Y and Residualizing 131I
J. Nucl. Med., June 1, 2001; 42(6): 967 - 974.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. G. Stabin, J. A. Siegel, R. B. Sparks, K. F. Eckerman, and H. B. Breitz
Contribution to Red Marrow Absorbed Dose from Total Body Activity: A Correction to the MIRD Method
J. Nucl. Med., March 1, 2001; 42(3): 492 - 498.
[Abstract] [Full Text]

Home page
 JNMHome page
D. Emfietzoglou, K. Kostarelos, and G. Sgouros
An Analytic Dosimetry Study for the Use of Radionuclide-Liposome Conjugates in Internal Radiotherapy
J. Nucl. Med., March 1, 2001; 42(3): 499 - 504.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
A. M. Ballangrud, W.-H. Yang, D. E. Charlton, M. R. McDevitt, K. A. Hamacher, K. S. Panageas, D. Ma, N. H. Bander, D. A. Scheinberg, and G. Sgouros
Response of LNCaP Spheroids after Treatment with an {{alpha}}-Particle Emitter (213Bi)-labeled Anti-Prostate-specific Membrane Antigen Antibody (J591)
Cancer Res., March 1, 2001; 61(5): 2008 - 2014.
[Abstract] [Full Text]

Home page
 JNMHome page
M. Lenarczyk, S. M. Goddu, D. V. Rao, and R. W. Howell
Biologic Dosimetry of Bone Marrow: Induction of Micronuclei in Reticulocytes After Exposure to 32P and 90Y
J. Nucl. Med., January 1, 2001; 42(1): 162 - 169.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. R. Colnot, J. J. Quak, J. C. Roos, A. van Lingen, A. J. Wilhelm, G. J. van Kamp, P. C. Huijgens, G. B. Snow, and G. A.M.S. van Dongen
Phase I Therapy Study of 186Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck
J. Nucl. Med., December 1, 2000; 41(12): 1999 - 2010.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. Cokgor, G. Akabani, C.-T. Kuan, H. S. Friedman, A. H. Friedman, R. E. Coleman, R. E. McLendon, S. H. Bigner, X.-G. Zhao, A. M. Garcia-Turner, et al.
Phase I Trial Results of Iodine-131-Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas
J. Clin. Oncol., November 15, 2000; 18(22): 3862 - 3872.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Tempero, P. Leichner, J. Baranowska-Kortylewicz, K. Harrison, S. Augustine, J. Schlom, J. Anderson, J. Wisecarver, and D. Colcher
High-Dose Therapy with 90Yttrium-labeled Monoclonal Antibody CC49: A Phase I Trial
Clin. Cancer Res., August 1, 2000; 6(8): 3095 - 3102.
[Abstract] [Full Text]

Home page
 JCOHome page
J. M. Vose, R. L. Wahl, M. Saleh, A. Z. Rohatiner, S. J. Knox, J. A. Radford, A. D. Zelenetz, G. F. Tidmarsh, R. J. Stagg, and M. S. Kaminski
Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
J. Clin. Oncol., March 13, 2000; 18(6): 1316 - 1323.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. C. Matthews, F. R. Appelbaum, J. F. Eary, D. R. Fisher, L. D. Durack, T. E. Hui, P. J. Martin, D. Mitchell, O. W. Press, R. Storb, et al.
Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome
Blood, August 15, 1999; 94(4): 1237 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. M. Behr, M. Behe, M. G. Stabin, E. Wehrmann, C. Apostolidis, R. Molinet, F. Strutz, A. Fayyazi, E. Wieland, S. Gratz, et al.
High-Linear Energy Transfer (LET) {{alpha}} versus Low-LET {beta} Emitters in Radioimmunotherapy of Solid Tumors: Therapeutic Efficacy and Dose-limiting Toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' Fragments in a Human Colonic Cancer Model
Cancer Res., June 1, 1999; 59(11): 2635 - 2643.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1993 by the Society of Nuclear Medicine.